Lipid-lowering therapy (LLT) in 1,100 cardiac rehabilitation patients with coronary heart disease: the LLT-R(ehabilitation) registry.

IF 2.8 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Frontiers in Cardiovascular Medicine Pub Date : 2025-04-24 eCollection Date: 2025-01-01 DOI:10.3389/fcvm.2025.1549935

Frank Noack, Kristina Eckrich, Heinz Völler, Bernhard Schwaab, Viktoria Heinze, Christa Bongarth, Manju Guha, Michael Richter, Nadja Schwark, Alexandra Strobel, Axel Schlitt

{"title":"Lipid-lowering therapy (LLT) in 1,100 cardiac rehabilitation patients with coronary heart disease: the LLT-R(ehabilitation) registry.","authors":"Frank Noack, Kristina Eckrich, Heinz Völler, Bernhard Schwaab, Viktoria Heinze, Christa Bongarth, Manju Guha, Michael Richter, Nadja Schwark, Alexandra Strobel, Axel Schlitt","doi":"10.3389/fcvm.2025.1549935","DOIUrl":null,"url":null,"abstract":"Background: Cardiac rehabilitation (CR) improves quality of life and prognosis in patients with coronary heart disease (CHD). The aim of the study was to evaluate effects of lipid-lowering therapy (LLT) in patients with CHD during and after CR.Methods: Data from prospective, multicenter registry including 1,100 patients with CHD undergoing CR in 6 German cardiac rehabilitation centers between 2016 and 2018 were analyzed.Results: The rate of statin-treated patients increased from 1,048 (96.3%) on admission to 1,062 (98.4%) at discharge (p < 0.001), falling to 644 (96.3%) and 609 (94.1%) at 3 and 12 months, respectively. Combination treatment with ezetimibe was effective in 8.9% of patients at admission and 28.5% at discharge (p < 0.001), and 23.5% and 25.8% after 3 month and 12 months, respectively. Titration of LLT during CR resulted in median LDL-C-values of 2.27 mmol/L at admission, 1.97 mmol/L at discharge (p < 0.001), 1.94 mmol/L after 3 months, and 1.94 mmol/L after 12 months, respectively.Conclusions: During CR, LLT was effectively instituted and titrated, resulting in a high rate of statin-treated patients and a significant reduction in LDL-C. From this study, we hypothesize that CR is efficacious for adherence to LLT.","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1549935"},"PeriodicalIF":2.8000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059688/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2025.1549935","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cardiac rehabilitation (CR) improves quality of life and prognosis in patients with coronary heart disease (CHD). The aim of the study was to evaluate effects of lipid-lowering therapy (LLT) in patients with CHD during and after CR.

Methods: Data from prospective, multicenter registry including 1,100 patients with CHD undergoing CR in 6 German cardiac rehabilitation centers between 2016 and 2018 were analyzed.

Results: The rate of statin-treated patients increased from 1,048 (96.3%) on admission to 1,062 (98.4%) at discharge (p < 0.001), falling to 644 (96.3%) and 609 (94.1%) at 3 and 12 months, respectively. Combination treatment with ezetimibe was effective in 8.9% of patients at admission and 28.5% at discharge (p < 0.001), and 23.5% and 25.8% after 3 month and 12 months, respectively. Titration of LLT during CR resulted in median LDL-C-values of 2.27 mmol/L at admission, 1.97 mmol/L at discharge (p < 0.001), 1.94 mmol/L after 3 months, and 1.94 mmol/L after 12 months, respectively.

Conclusions: During CR, LLT was effectively instituted and titrated, resulting in a high rate of statin-treated patients and a significant reduction in LDL-C. From this study, we hypothesize that CR is efficacious for adherence to LLT.

查看原文本刊更多论文

1100名冠心病心脏康复患者的降脂治疗（LLT）： LLT- r（康复）登记

背景：心脏康复（CR）可改善冠心病患者的生活质量和预后。该研究的目的是评估降脂治疗（LLT）在CR期间和之后对冠心病患者的影响。方法：对2016年至2018年6个德国心脏康复中心1100名接受CR的冠心病患者的前瞻性多中心注册数据进行分析。结果：他汀类药物治疗的患者比例从入院时的1048例（96.3%）增加到出院时的1062例（98.4%）（p p p）。结论：在CR期间，有效地建立和滴定了LLT，导致他汀类药物治疗的患者比例高，LDL-C显著降低。从本研究中，我们假设CR对坚持LLT有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Cardiovascular Medicine Medicine-Cardiology and Cardiovascular Medicine

CiteScore

3.80

自引率

11.10%

发文量

3529

审稿时长

14 weeks

期刊介绍： Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers? At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.